carbostyril has been researched along with Cardiovascular Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Alrwisan, AA; Antonelli, PJ; Brumback, BA; Wei, YJ; Winterstein, AG | 1 |
| Gluud, C; Hróbjartsson, A; Jakobsen, JC; Korang, SK; Safi, S; Sethi, NJ; Skoog, M | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Avallone, H; Cao, K; Capell, BC; Chen, X; Collins, FS; Conneely, KN; Erdos, MR; Faddah, DA; Ganesh, SK; Kolodgie, FD; Nabel, EG; Olive, M; Qu, X; San, H; Tavarez, UL; Virmani, R | 1 |
| Chung, KF; Felser, JM; Hu, H; Rueegg, P; Worth, H | 1 |
| Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
| Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X | 1 |
| Hartmann, RW; Hu, Q; Yin, L | 2 |
| Coffey, DB; John, N; Potter, PO | 1 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
1 review(s) available for carbostyril and Cardiovascular Diseases
| Article | Year |
|---|---|
Antibiotics for secondary prevention of coronary heart disease.
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Death, Sudden, Cardiac; Humans; Macrolides; Middle Aged; Myocardial Infarction; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2021 |
1 trial(s) available for carbostyril and Cardiovascular Diseases
| Article | Year |
|---|---|
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
9 other study(ies) available for carbostyril and Cardiovascular Diseases
| Article | Year |
|---|---|
Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study.
Topics: Adolescent; Adult; Aged; Amphetamines; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Central Nervous System Stimulants; Cohort Studies; Drug Interactions; Female; Humans; Male; Methylphenidate; Middle Aged; Quinolones; Retrospective Studies; Young Adult | 2019 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Mice; Progeria; Quinolones | 2008 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Scopolamine Derivatives; Smoking; Tiotropium Bromide | 2011 |
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Female; Humans; In Vitro Techniques; Liver; Quinolones; Solubility; Steroid 11-beta-Hydroxylase; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship | 2012 |
Onset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
Topics: Adrenergic alpha-Agonists; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Asthma; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Chest Pain; Child; Dyskinesia, Drug-Induced; Family; Female; Guanfacine; Humans; Lithium Chloride; Male; Mood Disorders; Neuropsychological Tests; Obesity; Paroxetine; Piperazines; Polypharmacy; Pregnancy; Prenatal Exposure Delayed Effects; Psychomotor Agitation; Quinolones; Selective Serotonin Reuptake Inhibitors; Smoking; Social Environment | 2012 |
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Female; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Quinolones; Risk Factors; Spectrometry, Mass, Electrospray Ionization | 2013 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |